Clinical Trial

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

Study acronym: REVISIT-C
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the risk of violent acts in real-world settings
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2022-01-12; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Recruiting 2022-03-25
Trial Details
NCT Number NCT05208190
Lead Sponsor New York State Psychiatric Institute
Collaborators: National Institute of Mental Health (NIMH)
Conditions Schizophrenia, Schizoaffective Disorder
Enrollment 280 participants
Start Date 2022-03-17
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-04